In contrast while there was no interaction between age and mutation status on mRNA abundance (adjusted p = 0.36, Fig. 4G), ATRX and age were synergistically associated with outcome, stratifying lower grade glioma patients into four groups (Fig. 4H). Here, ATRX is linked to central nervous system cancer.